PUBLISHER: DelveInsight | PRODUCT CODE: 1226608
PUBLISHER: DelveInsight | PRODUCT CODE: 1226608
"REMICADE Drug Insight and Market Forecast - 2032" report provides comprehensive insights about REMICADE for Rheumatoid Arthritis in the 7MM. A detailed picture of the REMICADE for Rheumatoid Arthritis in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the REMICADE for Rheumatoid Arthritis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REMICADE market forecast, analysis for Rheumatoid Arthritis in the 7MM, descriptive analysis such as SWOT, analysts' views, comprehensive overview of market competitors, and brief about emerging therapies in Rheumatoid Arthritis.
REMICADE is a product from Centocor, Infliximab, the active ingredient in REMICADE, is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα). It has a molecular weight of approximately 149.1 kilo daltons. Infliximab is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that include measures to inactivate and remove viruses, reduces the effects of a substance in the body that can cause inflammation.
REMICADE is used to treat RA, psoriatic arthritis any losing spondylitis and severe or disabling plaque psoriasis in adults.
REMICADE is supplied as a sterile, white, lyophilized powder for intravenous infusion. Following reconstitution with 10 mL of Sterile Water for Injection, USP, the resulting pH is approximately 7.2.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
REMICADE Analytical Perspective by DelveInsight
This report provides a detailed market assessment of REMICADE in Rheumatoid Arthritis in the 7MM, i.e., United States, EU4, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of REMICADE for Rheumatoid Arthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions